HQL Insider Trading

Insider Ownership Percentage: 10.06%
Insider Buying (Last 12 Months): $6,187,162.27
Insider Selling (Last 12 Months): $2,908,954.64

Abrdn Life Sciences Investors Insider Trading History Chart

This chart shows the insider buying and selling history at Abrdn Life Sciences Investors by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$357ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$6M-$4M-$2M$0$2M$4M$6MTotal Insider BuyingTotal Insider Selling

Abrdn Life Sciences Investors Share Price & Price History

Current Price: $12.06
Price Change: Price Decrease of -0.1 (-0.82%)
As of 04/4/2025 10:34 AM ET

This chart shows the closing price history over time for HQL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$12.19Closing price on 04/03/25:

SEC Filings (Institutional Ownership Changes) for Abrdn Life Sciences Investors (NYSE:HQL)

32.21% of Abrdn Life Sciences Investors stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at HQL by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$15Mbought$5.06MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M$0$10MTotal InflowsTotal Outflows
Abrdn Life Sciences Investors logo
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Read More on Abrdn Life Sciences Investors

Today's Range

Now: $12.06
Low: $12.00
High: $12.00

50 Day Range

MA: $13.47
Low: $12.19
High: $14.33

52 Week Range

Now: $12.06
Low: $12.02
High: $15.90

Volume

800 shs

Average Volume

98,902 shs

Market Capitalization

$329.85 million

P/E Ratio

N/A

Dividend Yield

15.29%

Beta

0.8

Who are the company insiders with the largest holdings of Abrdn Life Sciences Investors?

Abrdn Life Sciences Investors' top insider investors include:
  1. Saba Capital Management, LP (Major Shareholder)
  2. Daniel R Omstead (President)
  3. Bill Maher (Director)
  4. Kathleen Goetz (Director)
  5. Rose Dimartino (Director)
  6. Todd Reit (Director)
Learn More about top insider investors at Abrdn Life Sciences Investors.